Potential targets for the treatment of chronic lymphocytic leukemia (CLL).
| I. Neutralizing Target . | Clinically Available Antibody . | Small Molecule . |
|---|---|---|
| IL-8 | Yes (human) | No |
| IL-6 | Yes (preclinical) | Yes |
| TNF-α | Yes (humanized, neutralizing receptor) | Yes |
| IFN-γ | Yes (humanized) | Yes |
| SDF | Yes (preclinical) | No |
| VEGF | Yes (humanized) | Yes |
| bFGF | No | Yes |
| CD59 or CD55 | No | No |
| IL-4 | Yes | No (preclinical) |
| ZAP-70 | N/A | No (preclinical) |
| AKT | N/A | Yes (preclinical) |
| PI3 kinase | N/A | No (preclinical) |
| DNA methyl-transferase | N/A | Yes |
| Histone deacetylase | N/A | Yes |
| Phosphodiesterase | N/A | Yes |
| I. Neutralizing Target . | Clinically Available Antibody . | Small Molecule . |
|---|---|---|
| IL-8 | Yes (human) | No |
| IL-6 | Yes (preclinical) | Yes |
| TNF-α | Yes (humanized, neutralizing receptor) | Yes |
| IFN-γ | Yes (humanized) | Yes |
| SDF | Yes (preclinical) | No |
| VEGF | Yes (humanized) | Yes |
| bFGF | No | Yes |
| CD59 or CD55 | No | No |
| IL-4 | Yes | No (preclinical) |
| ZAP-70 | N/A | No (preclinical) |
| AKT | N/A | Yes (preclinical) |
| PI3 kinase | N/A | No (preclinical) |
| DNA methyl-transferase | N/A | Yes |
| Histone deacetylase | N/A | Yes |
| Phosphodiesterase | N/A | Yes |
| II. Cell Surface Targets . | ||
|---|---|---|
| CD20 | Yes (chimeric) | N/A |
| CD52 | Yes (humanized) | N/A |
| HLA-DR | Yes (humanized) | N/A |
| CD22 | Yes (humanized) | N/A |
| CD23 | Yes (chimeric) | N/A |
| CD47 | No | N/A |
| II. Cell Surface Targets . | ||
|---|---|---|
| CD20 | Yes (chimeric) | N/A |
| CD52 | Yes (humanized) | N/A |
| HLA-DR | Yes (humanized) | N/A |
| CD22 | Yes (humanized) | N/A |
| CD23 | Yes (chimeric) | N/A |
| CD47 | No | N/A |